Insilico Medicine makes a big move to solve Duchenne Muscular Dystrophy
My beloved company Insilico Medicine, Inc. today announced a research collaboration with computationally-driven biopharmaceutical company A2A Pharmaceuticals to develop novel small molecules for Duchenne Muscular Dystrophy (DMD) and other rare orphan diseases.
Duchenne is a fatal muscle disease that is caused by a mutation of the dystrophin gene. Since the disorder is X-linked recessive it affects approximately one in 3500 boys and 1 in 50 million girls. Starting with a muscle loss at 4 years old it worsens quickly and ends up with inability to walk at 12. And there is no cure yet.
I believe that there is no mission better than solving a problem with such a large deteriorating social and economical impact. And there is no better problem to apply advanced AI Technology that Insilico team has developed in recent years. For many years I was dreaming about highly impactful project able to change the life of the disabled children. Here it comes at Insilico. Support from a talented team of extremely experienced experts from A2A Pharma makes us even more confident in the indispensable success of the project. Please read more here.
Oh, and one more thing… a very similar strategy may be utilized to combat muscle wasting during Aging. And very recently we have published a paper how machine learning methods can be applied to search targets in muscle wasting.